Business Description
Immuno-Biological Laboratories Co Ltd
ISIN : JP3921300004
Total Employee Number:
63Description
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.59 | |||||
Equity-to-Asset | 0.86 | |||||
Debt-to-Equity | 0.1 | |||||
Debt-to-EBITDA | 0.55 | |||||
Interest Coverage | 211.02 | |||||
Piotroski F-Score | 7/9 | |||||
Altman Z-Score | 20.06 | |||||
Beneish M-Score | -2.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.1 | |||||
3-Year FCF Growth Rate | 116.3 | |||||
3-Year Book Growth Rate | 19.6 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.42 | |||||
9-Day RSI | 53.86 | |||||
14-Day RSI | 48.95 | |||||
3-1 Month Momentum % | -35.78 | |||||
6-1 Month Momentum % | -46.84 | |||||
12-1 Month Momentum % | 82.67 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.68 | |||||
Quick Ratio | 4.31 | |||||
Cash Ratio | 3.58 | |||||
Days Inventory | 426.87 | |||||
Days Sales Outstanding | 71.22 | |||||
Days Payable | 5.81 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 0.6 | |||||
Dividend Payout Ratio | 0.17 | |||||
Forward Dividend Yield % | 0.75 | |||||
5-Year Yield-on-Cost % | 0.6 | |||||
Shareholder Yield % | 0.79 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 70.35 | |||||
Operating Margin % | 27.99 | |||||
Net Margin % | 32.74 | |||||
EBITDA Margin % | 31.89 | |||||
FCF Margin % | 26.63 | |||||
OCF Margin % | 29.96 | |||||
ROE % | 19.69 | |||||
ROA % | 16.54 | |||||
ROIC % | 26.63 | |||||
3-Year ROIIC % | 60.67 | |||||
ROC (Joel Greenblatt) % | 45.94 | |||||
ROCE % | 17.62 | |||||
Years of Profitability over Past 10-Year | 3 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 28.13 | |||||
PE Ratio without NRI | 28.58 | |||||
Price-to-Owner-Earnings | 29.75 | |||||
PS Ratio | 9.21 | |||||
PB Ratio | 5.02 | |||||
Price-to-Tangible-Book | 5.03 | |||||
Price-to-Free-Cash-Flow | 34.58 | |||||
Price-to-Operating-Cash-Flow | 30.74 | |||||
EV-to-EBIT | 27.97 | |||||
EV-to-EBITDA | 26.36 | |||||
EV-to-Revenue | 8.4 | |||||
EV-to-FCF | 31.76 | |||||
Price-to-GF-Value | 1.72 | |||||
Price-to-Projected-FCF | 10.68 | |||||
Price-to-Median-PS-Value | 1.26 | |||||
Price-to-Graham-Number | 2.53 | |||||
| Price-to-Net-Current-Asset-Value | 7.36 | |||||
| Price-to-Net-Cash | 13.66 | |||||
Earnings Yield (Greenblatt) % | 3.57 | |||||
FCF Yield % | 2.89 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Immuno-Biological Laboratories Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil 円) | 1,004.987 | ||
| EPS (TTM) (円) | 35.33 | ||
| Beta | -2.5095 | ||
| 3-Year Sharpe Ratio | 0.52 | ||
| 3-Year Sortino Ratio | 4.72 | ||
| Volatility % | 582.37 | ||
| 14-Day RSI | 48.95 | ||
| 14-Day ATR (円) | 44.176989 | ||
| 20-Day SMA (円) | 970.15 | ||
| 12-1 Month Momentum % | 82.67 | ||
| 52-Week Range (円) | 464 - 3820 | ||
| Shares Outstanding (Mil) | 9.31 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Immuno-Biological Laboratories Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Immuno-Biological Laboratories Co Ltd Stock Events
| Event | Date | Price (円) | ||
|---|---|---|---|---|
| JPY 6.000000 Cash Dividend | 2026-03-30 | 1,405.00 (+0.93%) | ||
| 10:1 Stock Split | 2013-09-26 | 1,517.00 (-4.23%) |
Show
Entries
Immuno-Biological Laboratories Co Ltd Frequently Asked Questions
What is Immuno-Biological Laboratories Co Ltd(TSE:4570)'s stock price today?
The current price of TSE:4570 is 円994.00. The 52 week high of TSE:4570 is 円3820.00 and 52 week low is 円464.00.
When is next earnings date of Immuno-Biological Laboratories Co Ltd(TSE:4570)?
The next earnings date of Immuno-Biological Laboratories Co Ltd(TSE:4570) is .
Does Immuno-Biological Laboratories Co Ltd(TSE:4570) pay dividends? If so, how much?
The Dividend Yield %  of Immuno-Biological Laboratories Co Ltd(TSE:4570) is 0.6% (As of Today), Highest Dividend Payout Ratio of Immuno-Biological Laboratories Co Ltd(TSE:4570) was 0.17. The lowest was 0.17. And the median was 0.17. The  Forward Dividend Yield % of Immuno-Biological Laboratories Co Ltd(TSE:4570) is 0.75%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Immuno-Biological Laboratories Co Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers